Yelena Yuriy Janjigian, MD of Memorial Sloan-Kettering explains whether or not PDL-1 is a sufficient biomarker in gastric disease. She argues that clinicians should consider a one-stop next generation sequencing. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, New York.
